Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Diagnosing Osteoradionecrosis in Patients With Head and Neck Cancer That Is Primary, Has Come Back, or Has Spread to Other Places in the Body
Not Applicable
Recruiting
- Conditions
- Head and Neck Cancer
- Interventions
- Procedure: Dynamic Contrast-Enhanced Magnetic Resonance ImagingOther: Questionnaire Administration
- First Posted Date
- 2017-05-09
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1400
- Registration Number
- NCT03145077
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Decision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer
Not Applicable
Active, not recruiting
- Conditions
- Breast NeoplasmColorectal NeoplasmFemale Reproductive System NeoplasmHealth Care ProviderPlasma Cell MyelomaLymphoma
- Interventions
- Other: Best PracticeOther: Educational InterventionOther: Internet-Based InterventionOther: Questionnaire Administration
- First Posted Date
- 2017-05-05
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 130
- Registration Number
- NCT03141437
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Investigation of Sugammadex in Outpatient Urological Procedures
Phase 4
Completed
- Conditions
- Malignant Neoplasms of Urinary TractBladder Cancer
- Interventions
- First Posted Date
- 2017-05-03
- Last Posted Date
- 2020-09-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT03138967
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
Phase 2
Recruiting
- Conditions
- Recurrent Acute Lymphoblastic LeukemiaRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Adult Lymphoblastic LymphomaRecurrent Burkitt LeukemiaRecurrent Burkitt LymphomaRecurrent Childhood Lymphoblastic LymphomaRefractory Burkitt LeukemiaRefractory Lymphoblastic LymphomaRefractory Acute Lymphoblastic LeukemiaRefractory Burkitt Lymphoma
- Interventions
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT03136146
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss
Phase 1
Active, not recruiting
- Conditions
- Melanoma and Other Malignant Neoplasms of SkinMetastatic Melanoma
- Interventions
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT03131908
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia
Phase 1
Active, not recruiting
- Conditions
- Recurrent Acute Myeloid LeukemiaRecurrent Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic LeukemiaRefractory Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT03132454
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer
Early Phase 1
Completed
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8HER2/Neu NegativeProgesterone Receptor PositivePrognostic Stage IIIA Breast Cancer AJCC v8
- Interventions
- Biological: DurvalumabBiological: Tremelimumab
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT03132467
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Tranexamic Acid in Reducing Blood Loss in Patients With Pelvic Tumors Undergoing Hemipelvectomy Surgery
Early Phase 1
Recruiting
- Conditions
- Pelvic Mass
- Interventions
- Procedure: Hemipelvectomy
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT03128866
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
Phase 2
Recruiting
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 90
- Registration Number
- NCT03128879
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Pneumoperitoneum Management With Low vs. Higher Pressure
Phase 2
Withdrawn
- Conditions
- Malignant Neoplasms of Female Genital Organs
- Interventions
- Behavioral: QuestionnairesDevice: ConMed AirSeal Insufflation System (AIS) at Low PressureDevice: Conventional Insufflation System (CIS)Device: ConMed AirSeal Insufflation System (AIS) at Higher Pressure
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2019-05-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT03128281
© Copyright 2025. All Rights Reserved by MedPath